SHZ:002864

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd · SHZ · Healthcare · CNY · FY for 2025

Figures on this page computed 2026-11-08 13:10 UTC

Last close

n/aCNY

Market data

21.9xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
CNY
- computed
- Computed from the filing for 2025
13.7%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
8.4%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
1.8%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
0.07Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
CNY
- computed

What it pays out is the furthest below its sector's middle: 0.28 against 0.54 on the market's range.

All from 100

lens 2 of 9

Sales

374

2016-12-31 to 2025-12-31100 at the start374

Sales: 100.00 on 2016-12-31 to 373.53 on 2025-12-31, up 274%.

Profit

244

2016-12-31 to 2025-12-31100 at the start244

Profit: 100.00 on 2016-12-31 to 243.57 on 2025-12-31, up 144%.

Shares in issue

162

2016-12-31 to 2025-12-31100 at the start162

Shares in issue: 100.00 on 2016-12-31 to 161.50 on 2025-12-31, up 62%.

Sales is at 374, Profit is at 244, Shares in issue is at 162, against 100 in 2016.

Sales is at 374, Profit is at 244, Shares in issue is at 162, against 100 in 2016.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales, where the first year is 100374
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Profit, where the first year is 100244
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Shares in issue, where the first year is 100162
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY